Últimas notícias Notícias
Teresina, Brasil
Joined October 2016
- Tweets22
- Following54
- Followers45
- Likes12
Danilo Fonseca retweeted
ABC8 Advanced Breast Cancer Algorithms
8th International Consensus Guidelines for the management of advanced breast cancer (ABC8 Guidelines)
thebreastonline.com/article/…
Danilo Fonseca retweeted
Game-changer for premenopausal patients with N1 tumors
Still trying to figure out how to adopt the data from OPTIMA trial in my practice (and how to use OncotypeDx vs. PAM50 scoring/test). Who is the right patient? Should I pivot completely from other tests and just rely on PAM50?
@ErikaHamilton9 @PTarantinoMD @hoperugo @DrSGraff
Danilo Fonseca retweeted
The approval of T-DXd for the (neo)adjuvant treatment of HER2+ breast cancer will add an invaluable tool to our arsenal. Yet, in this era of right-sizing, not all patients require T-DXd treatment to be cured. Some thoughts in my recent JCO editorial. ascopubs.org/doi/full/10.120…
Danilo Fonseca retweeted
🧬🛡️ HER2-low tumors escape HER2 ADCs by losing the target
• True HER2 loss is uncommon in HER2-amplified disease but frequent in HER2-low, where HER2 isn’t oncogenic
• On HER2 ADC therapy, ~50% of tumors reduce HER2; among reducers, ~half become IHC 0
• Reduced HER2 → impaired ADC internalization, not payload resistance
• ERBB2 ECD variants disrupt antibody binding and phenocopy antigen loss
• Suggested strategy: multi-target payload delivery to bypass target dependence and improve durability
aacrjournals.org/cancerdisco…
Danilo Fonseca retweeted
Just out in @NEJM, the results of ASCENT-04, by @stolaney1 et al. Among patients with PD-L1+ mTNBC, first-line SG/pembro significantly improved PFS (11.2 vs 7.8 months, HR 0.65, p<0.001) compared with chemo/pembro. New standard of care for this population. nejm.org/doi/full/10.1056/NE…
Danilo Fonseca retweeted
Top #BreastCancer trials to watch ahead of @SABCSSanAntonio 2025, based on oncologists’ posts on 𝕏 — curated by @Larvol CLIN.
Explore more insights and data from #SABCS25: t.ly/S9em7
#LARVOL #SABCS2025 #Oncology #CancerResearch #CancerData #Oncologylnsights #BreastCancer #BCSM | @MamMa_mimumemo | @PTarantinoMD | @VKaklamani | @ArmandOrlandi | @shimoi_oncology | @drsarahsam | @kazuki_nozawa | @NeilVasan | @AbiSivaMD | @ncasasanta
Danilo Fonseca retweeted
<72hrs to #SABCS25, here is a📝 of 🔑 from #CommunityOncologists perspective. What’s on your radar?
- #lidERA
- #LORETTA
- #NSABP42
- #EMBER3
- #evERA
- #VIKTORIA1
- #ASCENT07
- #INSEMA
- #HER2Climb05
- #PREFER
#bcsm #OncTwitter @AACR @SABCSSanAntonio @OncoAlert
Danilo Fonseca retweeted
If you were still debating if osimertinib was better than gefitinib/Erlotinib: FLAURA OS update presented by @RamalingamMD at #ESMO19: MS OS 38.6 vs 31.8 mos, impressive 54% ⬇️ in CNS progression (HR 0.48), we still need better drugs for rare EGFR mutations and L858R. #lcsm
Danilo Fonseca retweeted
What after Osimertinib? Chemo?
Not always! Many targetable fusions drive osi resistance, and more and more promising TKIs are emerging
@OncoAlert #ESMO19
Resistance post osimertinib: acquired fusion in 16% of the NSCLC, all can be targeted (RET, FGFR3, BRAF, ALK)!!
Much more fusions than reported because most studies at resistance are on ctDNA.
16% is what we find with RNAseq on a fresh tissue biopsy (n=31). 1526P #ESMO2019
Danilo Fonseca retweeted
Brilliant presentation on role of ctDNA in detecting molecular relapse for early stage breast cancer by Nick Turner 1. Biology of breast cancer determined at initial diagnosis 2. Lead time (10mos) prior to clinical relapse 3. Consistent findings across all subtypes #ESMO19 #bcsm
Danilo Fonseca retweeted
Very proud of @RamalingamMD for outstanding presentation of OS from FLAURA! Exciting data with over 3 yr OS for osimertinib and over 25% of patients still on at 3 years. Real hope for our patients with EGFRmut NSCLC but still much room to go.
Danilo Fonseca retweeted
Dr. Hoyle presents the results of STAMPEDE @Prof_Nick_James stratifying M1 patients between low/high risk (LATITUDE) and low/high volume (CHAARTED). Similar benefit across subgrups. #ESMO18 – at Munich, Germany
Danilo Fonseca retweeted
JAEVILIN Renal 101 preliminary results presented by Dr. Motzer. Double the ORR with Avelumab+Axitinib, and improved PFS. Overall population and PDL1 positive poliarquia with similar benefit. OS still premature. #ESMO18 – at Munich, Germany
Danilo Fonseca retweeted
SOLAR-1: Randomized Phase 3 Study of Alpelisib (alpha-specific PI3k- Inhibitor) + Fulvestrant vs Fulvestrant alone. Results: PI3k mutation +ve PFS: 5.7m vs 11.0 m. Tox: Increased hyperglycemia (36% Grade3/4) and rash (10% Grade 3) #ESMO18
Danilo Fonseca retweeted
Agree. Currently TIL does not impact my clinical practice at all. #SABCS16 xitter.cf/jrgralow/status/806535…
More data on TILs being associated w/ good prognosis in TNBC - not sure how to use in treatment decision-making however #sabcs16
Danilo Fonseca retweeted
Hard to know what to make of extended duration AI rx. Gnant summary. #sabcs2016
